Jonathan Kahan and the Hogan Lovells Medical Device practice have completed the 2014 edition of Medical Device Development: Regulation and Law, a comprehensive 621-page treatise covering all aspects of medical device law and regulation. Since the 2009 edition of this book, new device legislation has been enacted and the FDA has issued dozens of important new guidances. The 2014 edition features in-depth analysis of these developments and addresses how emerging developments and trends are reshaping medical device and combination product regulations in the United States. Specifically, the 2014 edition reviews and analyzes the following critical developments since 2009:

  • Update on all the new provisions of the Food and Drug Administration Safety and Improvement Act of 2012  
  • New statutory provisions and guidances on device reclassification, including provisions relating to the direct de novo petition and reclassification by administrative order  
  • New statutory provisions and guidances related to humanitarian devices, including new rules on making profits on humanitarian devices and approvals for pediatric indications  
  • New statutory provisions and guidances on the CDRH appeal process, including procedures for appeal of “significant decisions”  
  • New statutory provisions and guidances on Section 522 postmarket surveillance orders  
  • New statutory provisions and requirements on custom devices, including the new “five times replication” rule 
  • New statutory provisions and guidances related to mobile medical apps and medical device software, including medical data software systems
  • Updates on the new organizational structure of CDRH, including revisions to the structure of the Office of Device Evaluation, the Office of Compliance, and the Office of In Vitro Diagnostics and Radiological Health  
  • Changes to the 510(k) pre-market notification process, including new policies on split predicates, when a device cannot be found to be SE, and the new priority review guidance  
  • Changes to the pre-submission process, including the end of the pre-IDE process and the birth of the “Q-sub”
  • New guidances on FDA’s “Refusal to Accept” policies relating to 510(k)s, PMA’s, and pre-submissions  
  • Update on the investigational device exemption process, including new guidances on early feasibility studies, FDA decisions for IDE investigations, design considerations for pivotal clinical device investigations, and good laboratory practices  
  • Changes to the pre-market approval application process, including birth of the e-copy and modifications to the advisory panel process  
  • New policies and guidances concerning in vitro diagnostic products, including the new guidances on Research Use Only/Investigational Use Only products, and in vitro “companion” diagnostics
  • Update on device compliance issues, including the 2013 draft medical device reporting guidance and recall procedures relating to product enhancements  
  • New guidances and cases relating to combination products incorporating medical devices